 |
 |
| Product ID |
Structure |
Product Name |
Purity |
Price |
Delete |
| A1-0090 |
 |
1-(tert-Butylperoxy)-1,2-benziodoxol-3(1H)-one |
>97%
|
$225/1g, 5g/POA |
Delete |
| A1-0153 |
 |
1-N-CBZ-2-Phenylpiperazine |
>96%
|
1g/$2455g/$980 |
Delete |
| JR8-N0179 |
 |
10-Hydroxycamptothecin |
98%
|
$600/20mg |
Delete |
| A1-0162 |
 |
2-(3-Nitrophenyl)piperazine |
95%
|
1g/$1685g/$645 |
Delete |
| JR6-L3898 |
 |
2-Pyrrolidinemethanol, a,a-bis(2,4-dimethoxyphenyl)-, (2S)- |
96%
|
|
Delete |
| JR6-L3888 |
 |
2-Pyrrolidinemethanol, a,a-bis[4-(hexyloxy)phenyl]-, (2S)- |
96%
|
|
Delete |
| A1-0093 |
 |
3-Hydroxyadamantancarboxylic acid |
97%
|
$225/10g |
Delete |
| JR6-L3281 |
 |
3-Pyridinecarboxylic acid, 1,6-dihydro-5-iodo-6-oxo-, methyl ester |
96%
|
|
Delete |
| JR6-L3283 |
 |
3-Pyridinecarboxylic acid, 5-bromo-1,6-dihydro-6-oxo-2-(trifluoromethyl)- |
96%
|
$480/1g, $780/2g, $1280/5g, $3980/25g |
Delete |
| JR6-L3280 |
 |
3-Pyridinecarboxylic acid, 5-chloro-1,6-dihydro-2-methyl-6-oxo-, ethyl ester |
96%
|
|
Delete |
| JR6-L3287 |
 |
3-Pyridinecarboxylic acid, 5-chloro-1,6-dihydro-6-oxo-, methyl ester |
96%
|
|
Delete |
| JR6-L6765 |
 |
3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-5-(trifluoromethyl)- |
96%
|
$780/1g, $2480/5g, $6980/25g |
Delete |
| JR6-L6761 |
 |
3H-Pyrazol-3-one, 2-(3-chlorophenyl)-2,4-dihydro-5-(trifluoromethyl)- |
96%
|
$680/1g, $2980/5g |
Delete |
| JR6-L3937 |
 |
Benzeneacetonitrile, 2,3-difluoro-a-oxo- |
96%
|
|
Delete |
| JR6-L6748 |
 |
Benzoic acid, 4-[2,5-dihydro-5-oxo-3-(trifluoromethyl)-1H-pyrazol-1-yl]- |
96%
|
$780/1g, $2480/5g, $6980/25g |
Delete |
| JR8-N0186 |
 |
Coptisine |
98%
|
$700/20mg |
Delete |
| JR8-N0182 |
 |
Dihydroartemisinin |
98%
|
$98/1g, $198/5g, $518/25g, $918/100g, bulky available |
Delete |
| A1-0066 |
 |
Furan-2(5H)-one |
97%
|
|
Delete |
| A1-0152 |
 |
N-1-CBZ-2-Ethylpiperazine |
>96%
|
1g/$2455g/$980 |
Delete |
| JR6-L3889 |
 |
Pyrrolidine, 2-[di-2-naphthalenyl[(trimethylsilyl)oxy]methyl]-, (2S)- |
96%
|
|
Delete |
|
Continue browsing products
Quote/Order
Inquiry
|
|
|
 |
 |
 |